DDInter1139 DDInter1825
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer.
Mefenamic acid {u} (Compound) resembles {v} (Compound) Diclofenac
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Diclofenac
Diclofenac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tofacitinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tofacitinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} (Compound) resembles {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tofacitinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Lorlatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Niflumic Acid
Niflumic Acid {u} (Compound) resembles {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Meclofenamic acid
Meclofenamic acid {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diclofenac
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Esomeprazole
Esomeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Mefenamic acid (Compound) resembles Diclofenac (Compound) and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Mefenamic acid (Compound) resembles Acetylsalicylic acid (Compound) and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Mefenamic acid (Compound) resembles Diclofenac (Compound) and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Mefenamic acid (Compound) resembles Acetylsalicylic acid (Compound) and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Mefenamic acid (Compound) resembles Ketoprofen (Compound) and Ketoprofen (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Mefenamic acid (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Mefenamic acid (Compound) resembles Niflumic Acid (Compound) and Niflumic Acid (Compound) resembles Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Tofacitinib
Mefenamic acid (Compound) resembles Meclofenamic acid (Compound) and Meclofenamic acid (Compound) resembles Diclofenac (Compound) and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Mefenamic acid (Compound) resembles Acetylsalicylic acid (Compound) and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Esomeprazole and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Mefenamic acid (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib